Business
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced strategic updates ahead of its participation in the 15th Annual LifeSci Partners Corporate Access Event taking place in San Francisco, CA, from January 12-14
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"FDA End-of-Phase 2 meeting scheduled to take place in the first quarter of 2026 for the chronic cough program in patients with idiopathic pulmonary fibrosis","length":156,"tagName":"p","attribs":{}},{"type":"text","content":"Phase 2b refractory chronic cough trial planned to initiate in the first half of 2026 ","length":85,"tagName":"p","attribs":{}},{"type":"text","content":"NEW HAVEN, Conn., Jan. 8, 2026 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced strategic updates ahead of its participation in the 15th Annual LifeSci Partners Corporate Access Event taking place in San Francisco, CA, from January 12-14, 2026. This event will be held during the week of the annual J.P. Morgan Healthcare Conference.","length":653,"tagName":"p"},{"type":"image","alt":"Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":191,"url":"https://media.zenfs.com/en/prnewswire.com/1d24c1eb01896fcef1cee2fa511338ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/38_zYmADMS1aphP0L6NgsQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMzNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1d24c1eb01896fcef1cee2fa511338ec","width":400,"height":191}},"href":"https://mma.prnewswire.com/media/1504281/Trevi_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We are excited as we begin 2026 to continue the clinical development of Haduvio in our key chronic cough indications," said Jennifer Good, President and CEO of Trevi Therapeutics. "We have an End-of-Phase 2 meeting scheduled with the FDA, and we hope to align on our development program for the treatment of chronic cough in patients with IPF and then initiate that program. We have also been preparing to initiate a Phase 2b trial in RCC in the first half of this year. We expect that 2026 will be a ...